Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus.
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D001706:Biopsy; D002699:Chlorambucil / Q000627:therapeutic use; D003165:Complement System Proteins / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000503:physiopathology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000503:physiopathology; D007677:Kidney Function Tests; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009504:Neutrophils; D011241:Prednisone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D013997:Time Factors; D014511:Uremia / Q000209:etiology
D000974:Antibodies, Antinuclear; D002699:Chlorambucil; D003165:Complement System Proteins; D011241:Prednisone